A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury (SCI)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00725790 |
Recruitment Status
: Unknown
Verified July 2008 by China Rehabilitation Research Center.
Recruitment status was: Not yet recruiting
First Posted
: July 30, 2008
Last Update Posted
: July 30, 2008
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Erectile Dysfunction | Drug: Vardenafil Drug: Placebo | Phase 4 |
According to the Massachusetts Male Aging Study, erectile dysfunction (ED) is estimated as affecting approximately 30 million American men and 100 million men worldwide. The study also reported that approximately 52% of males aged 40-70 experience some degree of ED. Prevalence has been shown to increase with age, with an estimated 40% of the responders experiencing ED at age 40, whereas, 67% had difficulties by age 75.
Considerable advances have been made since the NIH Consensus statement that defined ED as the persistent inability to achieve and maintain an erection sufficient for satisfactory sexual performance. However, one thing remains the same, sexuality continues to be a driving force in our society today. Many men with erectile dysfunction suffer from issues of self esteem, self worth, the creation and maintenance of interpersonal relationships and in general, wrestle with an overall altered sense of wellbeing. Damage to personal relationships can ensue; and the anger, depression, and anxiety engendered spill over into all aspects of life.
VIAGRA(sildenafil), administered as a flexible-dose regimen, has demonstrated to be an effective and well-tolerated treatment for ED in spinal cord injury sufferers.This is a multi-centre, prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury.
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 350 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Multi-Centre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury |
Study Start Date : | August 2008 |
Estimated Primary Completion Date : | August 2009 |
Estimated Study Completion Date : | September 2009 |

Arm | Intervention/treatment |
---|---|
Experimental: A
Vardenafil treatment group
|
Drug: Vardenafil
10 mg vardenafil on demand treatment for first 4 weeks. A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period. A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period. |
Placebo Comparator: B
Placebo treatment group
|
Drug: Placebo
10 mg placebo on demand treatment for first 4 weeks. A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period. A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period. |
- EF domain score of IIEF [ Time Frame: week 12 ]
- IIEF/SEP/GAQ [ Time Frame: at week 4, week 8, week 12 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult) |
Sexes Eligible for Study: | Male |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- 18-65 years old, had ED more than 6 months
- Traumatic spinal cord injury was the sole cause of ED
- Patients had been in a heterosexual relationship for at least 1 month
- Documented written informed consent.
Exclusion Criteria:
- Presence of symptomatic active urinary tract infection, indwelling urethral catheter.
- Patients who have used any kind of PDE-5i prior to the study
- Other conditions that may cause ED such as history of radical prostatectomy, diabetes mellitus, anatomic penile abnormality and primary hypoactive sexual desire
- History of symptomatic uncontrolled autonomic dysreflexia; postural hypotension
- Cardiovascular abnormality such as unstable angina pectoris, myocardial infarction or stroke, electrocardiographic ischemia or life-threatening arrhythmia, resting systolic blood pressure>170 or <90 mmHg, diastolic pressure >110mmHg
- Retinitis pigmentosa
- Patients who currently were using any of the following medications: nitrates, nitric oxide donors, androgen or antiandrogen, anticoagulants, trazodone, erythromycin, azole antifungals, other contraindicative medications in package insert
- Other contraindications in package insert

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00725790
Contact: Li-Min Liao, Dr. | +86 010 67563322 ext 3702 | lmliao@263.net | |
Contact: Yan-He Ju, Dr. | +86 010 87458636 | jyhgjj@163.com |
China, Beijing | |
Beijing Boai Hospital Affiliated to China Rehabilitation Research Center | Not yet recruiting |
Beijing, Beijing, China, 100077 | |
Contact: Yan-He Ju, Dr. +86 010 87458636 jyhgjj@163.com | |
Principal Investigator: Li-Min Liao, Dr. |
Principal Investigator: | Li-Min Liao, Dr. | China Rehabilitation Research Center |
Publications:
Responsible Party: | Professor Li-Min Liao, China Rehabilitation Research Center |
ClinicalTrials.gov Identifier: | NCT00725790 History of Changes |
Other Study ID Numbers: |
SCI-01 |
First Posted: | July 30, 2008 Key Record Dates |
Last Update Posted: | July 30, 2008 |
Last Verified: | July 2008 |
Keywords provided by China Rehabilitation Research Center:
Erectile Dysfunction Spinal Cord Injury |
Additional relevant MeSH terms:
Spinal Cord Injuries Erectile Dysfunction Spinal Cord Diseases Central Nervous System Diseases Nervous System Diseases Trauma, Nervous System Wounds and Injuries Sexual Dysfunction, Physiological Genital Diseases, Male |
Sexual Dysfunctions, Psychological Mental Disorders Vardenafil Dihydrochloride Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |